BiotechTube

Granisetron + Ondansetron

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malignant Glioma

Conditions

Malignant Glioma

Trial Timeline

— → —

NCT ID
NCT01952886

About Granisetron + Ondansetron

Granisetron + Ondansetron is a phase 2 stage product being developed by Kyowa Kirin for Malignant Glioma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01952886. Target conditions include Malignant Glioma.

What happened to similar drugs?

5 of 20 similar drugs in Malignant Glioma were approved

Approved (5) Terminated (2) Active (13)
✅Deep Neuromuscular Blockade (NMB) + Moderate Neuromuscular Blockade (NMB) + Sugammadex + NeostigmineMerckApproved
✅Rocuronium + Sugammadex + Neostigmine + GlycopyrrolateMerckApproved
✅ZelborafRocheApproved
✅Atezolizumab Injection [Tecentriq]RocheApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01952886Phase 2Withdrawn

Competing Products

20 competing products in Malignant Glioma

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
39
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Tadalafil + GemcitabineEli LillyPhase 1
29
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
39
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
32
DS-1123Daiichi SankyoPhase 1
29
DS-8201aDaiichi SankyoPhase 1
29
DS-5573aDaiichi SankyoPhase 1
21
DS-6051bDaiichi SankyoPhase 1
29
U3-1565Daiichi SankyoPhase 1
29
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
39
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
29
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
39
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
39
CP-461Astellas PharmaPhase 2
27
enfortumab vedotinAstellas PharmaPhase 1
29
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
36
Perampanel + Standard of CareEisaiPhase 1/2
32
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
40